1. Home
  2. REVB vs QNRX Comparison

REVB vs QNRX Comparison

Compare REVB & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • QNRX
  • Stock Information
  • Founded
  • REVB 2020
  • QNRX 2018
  • Country
  • REVB United States
  • QNRX United States
  • Employees
  • REVB N/A
  • QNRX N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • QNRX Medical/Dental Instruments
  • Sector
  • REVB Health Care
  • QNRX Health Care
  • Exchange
  • REVB Nasdaq
  • QNRX Nasdaq
  • Market Cap
  • REVB 4.4M
  • QNRX 4.3M
  • IPO Year
  • REVB N/A
  • QNRX N/A
  • Fundamental
  • Price
  • REVB $2.87
  • QNRX $7.78
  • Analyst Decision
  • REVB
  • QNRX
  • Analyst Count
  • REVB 0
  • QNRX 0
  • Target Price
  • REVB N/A
  • QNRX N/A
  • AVG Volume (30 Days)
  • REVB 87.7K
  • QNRX 2.6K
  • Earning Date
  • REVB 11-07-2025
  • QNRX 11-06-2025
  • Dividend Yield
  • REVB N/A
  • QNRX N/A
  • EPS Growth
  • REVB N/A
  • QNRX N/A
  • EPS
  • REVB N/A
  • QNRX N/A
  • Revenue
  • REVB N/A
  • QNRX N/A
  • Revenue This Year
  • REVB N/A
  • QNRX N/A
  • Revenue Next Year
  • REVB N/A
  • QNRX N/A
  • P/E Ratio
  • REVB N/A
  • QNRX N/A
  • Revenue Growth
  • REVB N/A
  • QNRX N/A
  • 52 Week Low
  • REVB $2.11
  • QNRX $5.01
  • 52 Week High
  • REVB $60.48
  • QNRX $54.95
  • Technical
  • Relative Strength Index (RSI)
  • REVB 56.54
  • QNRX 55.81
  • Support Level
  • REVB $2.65
  • QNRX $7.39
  • Resistance Level
  • REVB $2.88
  • QNRX $7.74
  • Average True Range (ATR)
  • REVB 0.19
  • QNRX 0.17
  • MACD
  • REVB 0.03
  • QNRX 0.10
  • Stochastic Oscillator
  • REVB 88.00
  • QNRX 100.00

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: